| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/30/2013 | US20130136692 Molecular signature of cancer |
| 05/30/2013 | CA2856866A1 Administration of alpha4beta7 hetero-dimer-specific antibody |
| 05/30/2013 | CA2856638A1 Malaria vaccine |
| 05/30/2013 | CA2856582A1 Il-1 binding proteins |
| 05/30/2013 | CA2856297A1 Binding molecules specific for her3 and uses thereof |
| 05/30/2013 | CA2856258A1 Monoclonal antibodies specific for the m2-1 antigen of respiratory syncytial virus (rsv) |
| 05/30/2013 | CA2856252A1 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles |
| 05/30/2013 | CA2855699A1 Anti-human trop-2 antibody having an antitumor activity in vivo |
| 05/30/2013 | CA2851210A1 Combination therapy using anti-cd20 antibody and human il-15 |
| 05/29/2013 | EP2597151A2 Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods |
| 05/29/2013 | EP2597104A1 Antibodies against human TWEAK and uses thereof |
| 05/29/2013 | EP2596802A1 Pharmaceutical composition for treatment of allergic reactions |
| 05/29/2013 | EP2596801A1 Methods for treating cancer with mva |
| 05/29/2013 | EP2596114A2 Domain insertion immunoglobulin |
| 05/29/2013 | EP2596025A1 Methods for cancer management targeting co-029 |
| 05/29/2013 | EP2596023A2 Compositions and methods featuring il-6 and il-21 antagonists |
| 05/29/2013 | EP2596022A1 Anti-il-23 heterodimer specific antibodies |
| 05/29/2013 | EP2596021A2 A method of treating alzheimer's disease |
| 05/29/2013 | EP2596020A2 Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy |
| 05/29/2013 | EP2596019A2 A method of treating attention deficit hyperactivity disorder |
| 05/29/2013 | EP2596018A2 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 05/29/2013 | EP2596017A1 Cross-protective pathogen protection, methods and compositions thereof |
| 05/29/2013 | EP2595657A2 Anti-tumor antigen antibodies and methods of use |
| 05/29/2013 | EP2595656A1 Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid |
| 05/29/2013 | EP2595655A2 Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition |
| 05/29/2013 | EP2595654A1 Concentrated human immunoglobulin composition |
| 05/29/2013 | EP2595653A1 Influenza vaccine |
| 05/29/2013 | EP2595652A1 Parapoxvirus vectors |
| 05/29/2013 | EP2595644A1 Amyloid-beta clearance |
| 05/29/2013 | CN1956738B Antibodies to MAdCAM |
| 05/29/2013 | CN1911965B Binding domain-immunoglobulin fusion proteins |
| 05/29/2013 | CN1829740B Connective tissue growth factor antibodies |
| 05/29/2013 | CN1813061B Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 05/29/2013 | CN1705491B Optimized Fc variants and methods for their generation |
| 05/29/2013 | CN1582165B Antibodies to CD40 |
| 05/29/2013 | CN103124743A RON binding constructs and methods of use thereof |
| 05/29/2013 | CN103124741A Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 05/29/2013 | CN103124737A Immunogenic composition or vaccine against Gram-negative bacterial, for example neiserial, infrection or disease |
| 05/29/2013 | CN103124564A Compositions and methods useful for stabilizing protein-containing formulations |
| 05/29/2013 | CN103124561A Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| 05/29/2013 | CN103122360A Chimeric adenoviral vectors |
| 05/29/2013 | CN103122354A Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
| 05/29/2013 | CN103122336A Goose parvovirus H-strain and application thereof in preventing and treating gosling plague |
| 05/29/2013 | CN103122031A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 05/29/2013 | CN103120653A Oral pharmaceutical composition |
| 05/29/2013 | CN103120644A Amphiphilic segmented copolymer micelle of macromolecules of biologically functional protein and preparation and application thereof |
| 05/29/2013 | CN103120640A Embolic agent as well as preparation method and use method thereof |
| 05/29/2013 | CN102219750B N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| 05/29/2013 | CN102124100B A monoclonal antibody specifically binding to VEGF and the hybridoma secreting same and uses thereof |
| 05/29/2013 | CN101978054B Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 05/29/2013 | CN101926995B Asparagus immunologic adjuvant and influenza vaccines containing same |
| 05/29/2013 | CN101891820B Humanized anti-human von willebrand disease factor monoclonal antibody and application thereof |
| 05/29/2013 | CN101868249B Medicaments and methods for treating mesothelioma |
| 05/29/2013 | CN101790383B Production of an homogeneous vaccine preparation for cancer treatment |
| 05/29/2013 | CN101636168B Sp35 antibodies and uses thereof |
| 05/29/2013 | CN101553233B Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| 05/29/2013 | CN101374863B Immunoglobulins directed against NOGO |
| 05/29/2013 | CN101287443B Pulse releasing system controlled by pH, preparation method and application thereof |
| 05/29/2013 | CN101189028B Identification and engineering of antibodies with variant Fc regions and methods of using the same |
| 05/28/2013 | US8450464 Human monoclonal antibodies that bind CXCR4 |
| 05/28/2013 | US8450288 For introduction of a disc prosthesis or implant; involves providing substance(s) beneficial to the intervertebral disc through a cannulated element |
| 05/28/2013 | US8450274 DKK2 protein and use thereof |
| 05/28/2013 | US8450273 Fusion proteins of collagen-binding domain and parathyroid hormone |
| 05/28/2013 | US8450086 Bacterial membrane protein secretion |
| 05/28/2013 | US8450067 Method for obtaining anti-idiotype antibodies |
| 05/28/2013 | US8450055 Malaria antigen screening method |
| 05/28/2013 | US8449894 Aspergillus vaccine preparation and methods of making and using thereof |
| 05/28/2013 | US8449893 Compositions and dosage regimes comprising a clostridial vaccine and levamisole |
| 05/28/2013 | US8449892 S. agalactiae antigens I and II |
| 05/28/2013 | US8449891 Recombinant flagellin protein and preparation and use thereof |
| 05/28/2013 | US8449889 Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| 05/28/2013 | US8449888 Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells |
| 05/28/2013 | US8449887 Anti-chikungunya monoclonal antibodies and uses thereof |
| 05/28/2013 | US8449886 Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| 05/28/2013 | US8449885 Anti-VEGF antibodies |
| 05/28/2013 | US8449884 Clotting factor-fc chimeric proteins to treat hemophilia |
| 05/28/2013 | US8449883 Compositions and methods for the diagnosis and treatment of tumor |
| 05/28/2013 | US8449882 Anti-EPHA2 antibody |
| 05/28/2013 | US8449881 Anti-α-enolase I antibodies for diagnosis and treatment of α-enolase I-associated diseases |
| 05/28/2013 | US8449875 Targeting pseudotyped retroviral vectors |
| 05/28/2013 | US8449874 Interleukin-1 muteins linked to virus-like particles to treat IL-1 associated diseases |
| 05/28/2013 | US8449865 Drying process |
| 05/28/2013 | US8449863 Stabilized uncoated particles of reversed liquid crystalline phase materials |
| 05/28/2013 | US8449489 Method and means for treating inflammatory bowel disease |
| 05/28/2013 | CA2731995C Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| 05/28/2013 | CA2727715C Vaccine composition |
| 05/28/2013 | CA2605583C Polyinosinic acid-polycytidylic acid-based adjuvant |
| 05/28/2013 | CA2577918C Vaccine composition against hepatitis c virus |
| 05/28/2013 | CA2563399C Stabilized biodegradable neurotoxin implants |
| 05/28/2013 | CA2563260C Methods of treating autoimmune and inflammatory diseases |
| 05/28/2013 | CA2535338C Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers |
| 05/28/2013 | CA2521649C Composition and uses of galectin antagonists |
| 05/28/2013 | CA2517258C Recombinant measles virus comprising dengue or west nile virus polynucleotides, and their use in vaccinal and therapeutic applications |
| 05/28/2013 | CA2514794C Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 05/28/2013 | CA2502904C Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| 05/28/2013 | CA2494372C Antibodies that immunospecifically bind to trail receptors |
| 05/28/2013 | CA2481108C Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase |
| 05/28/2013 | CA2476773C Monoclonal antibodies against extracellular loops of c5ar |
| 05/28/2013 | CA2459769C Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 05/28/2013 | CA2448620C Vaccination against the feline immunodeficiency virus |